Literature DB >> 3396492

Serum and tissue concentrations of cefoxitin and cefotaxime in women undergoing hysterectomy.

R L White1, C H Nightingale, R Quintiliani, K F Whitaker, R F Jones, W H Tripp.   

Abstract

In a comparative study of serum and uterine tissue concentrations of cefoxitin and cefotaxime in patients undergoing hysterectomy, 40 patients were randomised to receive either cefoxitin 2g or cefotaxime 2g by intravenous administration. Serum samples were obtained before drug administration, at the ligation of the uterine arteries and at the end of surgery. Cefoxitin, cefotaxime and desacetylcefotaxime concentrations were determined by high performance liquid chromatography. The composite serum half-lives (determined by linear regression) for cefoxitin, cefotaxime and desacetylcefotaxime were 0.8, 0.7 and 2.1 hours, respectively. Although serum concentrations were higher for cefotaxime than for cefoxitin after a 2g dose, the uterine concentrations (at 40 mins) of cefoxitin were higher (51 micrograms/g vs 16 micrograms/g) than those of cefotaxime. After a 2g dose of cefotaxime the desacetylcefotaxime peak uterine concentration was 8 micrograms/g. Both drugs achieved adequate concentrations in serum and uterine tissue to prevent and treat infections caused by common Enterobacteriaceae such as Escherichia coli, with cefotaxime having a longer apparent duration of activity. However, cefoxitin provided serum and uterine concentrations above the minimum inhibitory concentration of Bacteroides fragilis for a longer period than did cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396492     DOI: 10.2165/00003495-198800352-00016

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

1.  The effective period of preventive antibiotic action in experimental incisions and dermal lesions.

Authors:  J F Burke
Journal:  Surgery       Date:  1961-07       Impact factor: 3.982

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Study of cefotaxime in the treatment of obstetric and gynaecological infections.

Authors:  J H Soutoul; R Quentin; G Boscq; C Chazara; D Prieur
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

Review 4.  First and second generation cephalosporins.

Authors:  R Quintiliani; M French; C H Nightingale
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

5.  A decisive period in the antibiotic prophylaxis of cutaneous lesions caused by Bacteroides fragilis in guinea pigs.

Authors:  M Shapiro; D Shimon; U Freund; T Sacks
Journal:  J Infect Dis       Date:  1980-04       Impact factor: 5.226

6.  Anaerobic infections.

Authors:  S M Finegold
Journal:  Surg Clin North Am       Date:  1980-02       Impact factor: 2.741

7.  Effect of protein binding on the penetration of nonmetabolized cephalosporins into atrial appendage and pericardial fluids in open-heart surgical patients.

Authors:  C H Nightingale; J J Klimek; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Cefoxitin for prophylaxis in premenopausal women undergoing vaginal hysterectomy.

Authors:  D L Hemsell; F G Cunningham; S Kappus; B Nobles
Journal:  Obstet Gynecol       Date:  1980-11       Impact factor: 7.661

9.  Aminoglycoside-selected subpopulations of Pseudomonas aeruginosa: characterization and virulence in normal and leukopenic mice.

Authors:  A U Gerber; W A Craig
Journal:  J Lab Clin Med       Date:  1982-11

10.  Cefoxitin sodium: double-blind vaginal hysterectomy prophylaxis in premenopausal patients.

Authors:  A Mickal; D Curole; C Lewis
Journal:  Obstet Gynecol       Date:  1980-08       Impact factor: 7.661

  10 in total
  2 in total

Review 1.  Antibiotic prophylaxis in hysterectomy and induced abortion. A review of the evidence.

Authors:  E T Houang
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

2.  Cefminox versus Cefoxitin in Hysterectomy Prophylaxis : Clinical Efficacy and Serum and Tissue Concentrations.

Authors:  R Garrido; A Novo; S Quintana; M A Macía; L Carrasco; M J de Dios; J M Romo; M Sánchez; M Vargas; M Maciá; F Lapuente; Y Mieza; P Coronet; M Gimeno; A J Carcas; J Frías; V Caballero Fernández
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.